DE69837896D1 - Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität - Google Patents

Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität

Info

Publication number
DE69837896D1
DE69837896D1 DE69837896T DE69837896T DE69837896D1 DE 69837896 D1 DE69837896 D1 DE 69837896D1 DE 69837896 T DE69837896 T DE 69837896T DE 69837896 T DE69837896 T DE 69837896T DE 69837896 D1 DE69837896 D1 DE 69837896D1
Authority
DE
Germany
Prior art keywords
cea
peptides
carcinoembryonic antigen
antagonist activity
tachykinin antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69837896T
Other languages
English (en)
Other versions
DE69837896T2 (de
Inventor
Jeffrey Schlom
Nee Barzaga Maria Elen Salazar
Sam Zaremba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE69837896D1 publication Critical patent/DE69837896D1/de
Application granted granted Critical
Publication of DE69837896T2 publication Critical patent/DE69837896T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464482—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69837896T 1997-10-10 1998-09-22 Peptidagonisten von karzinoembryonalem Antigen (CEA) Expired - Fee Related DE69837896T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6158997P 1997-10-10 1997-10-10
US61589P 1997-10-10

Publications (2)

Publication Number Publication Date
DE69837896D1 true DE69837896D1 (de) 2007-07-19
DE69837896T2 DE69837896T2 (de) 2008-02-14

Family

ID=22036775

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69837896T Expired - Fee Related DE69837896T2 (de) 1997-10-10 1998-09-22 Peptidagonisten von karzinoembryonalem Antigen (CEA)
DE69824023T Expired - Lifetime DE69824023T2 (de) 1997-10-10 1998-09-22 Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69824023T Expired - Lifetime DE69824023T2 (de) 1997-10-10 1998-09-22 Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind

Country Status (11)

Country Link
EP (1) EP1017810B1 (de)
JP (1) JP4291508B2 (de)
AT (2) ATE364048T1 (de)
AU (1) AU745863B2 (de)
CA (1) CA2308127C (de)
CY (1) CY1107706T1 (de)
DE (2) DE69837896T2 (de)
DK (1) DK1447414T3 (de)
ES (2) ES2217585T3 (de)
PT (1) PT1447414E (de)
WO (1) WO1999019478A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
ES2447115T3 (es) * 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
DK1227837T3 (da) 1999-10-22 2008-09-15 Aventis Pasteur Fremgangsmåde til introduktion og/eller fremskyndelse af et immunrespons på et tumorantigen
CA2416893A1 (en) * 2000-07-31 2002-02-07 Aventis Pasteur Limited Modified cea and uses thereof
AU2003203140A1 (en) * 2002-01-17 2003-07-30 Pharmexa A/S Immunogenic carcinoembryonic antigen (cea)
US6949629B2 (en) 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins
EP2301356A3 (de) * 2002-12-04 2012-05-30 Baylor Research Institute Schnelles Ein-Schritt-Verfahren zur Erzeugung eines Antigen-geladenen dendritischen Impfstoffs aus Vorläufern
CN102370974B (zh) * 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US7457855B2 (en) 2004-04-30 2008-11-25 Aol Llc Network configuration management
EP3061462B1 (de) 2007-07-02 2019-02-27 Etubics Corporation Verfahren und zusammensetzungen zur erzeugung eines adenovirusvektors zur verwendung mit mehreren impfungen
WO2009015841A1 (en) 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
JP5792630B2 (ja) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
ES2660597T3 (es) 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
KR102193635B1 (ko) 2015-01-09 2020-12-21 이투빅스 코포레이션 복합 면역요법을 위한 방법 및 조성물
WO2016112188A1 (en) 2015-01-09 2016-07-14 Etubics Corporation Methods and compositions for ebola virus vaccination
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3399943B2 (ja) * 1991-05-06 2003-04-28 アメリカ合衆国 癌胎児性抗原を発現する組換えウイルスとその使用方法
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof

Also Published As

Publication number Publication date
DE69824023T2 (de) 2005-05-12
CA2308127C (en) 2011-03-22
AU745863B2 (en) 2002-04-11
JP2002500002A (ja) 2002-01-08
ATE364048T1 (de) 2007-06-15
WO1999019478A1 (en) 1999-04-22
ES2286530T3 (es) 2007-12-01
EP1017810A1 (de) 2000-07-12
DK1447414T3 (da) 2007-09-10
ES2217585T3 (es) 2004-11-01
ATE267213T1 (de) 2004-06-15
CY1107706T1 (el) 2013-04-18
EP1017810B1 (de) 2004-05-19
JP4291508B2 (ja) 2009-07-08
PT1447414E (pt) 2007-07-18
AU9500498A (en) 1999-05-03
DE69837896T2 (de) 2008-02-14
DE69824023D1 (de) 2004-06-24
CA2308127A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
DE69837896D1 (de) Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
EA199800946A1 (ru) Концентрированный препарат антител
ATE272070T1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
DE69533923D1 (de) Cytokinin-designiertes lerk-5
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
DE69431060D1 (de) Klonierte glutaminsäure-decarboxylase
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
DK0529023T3 (da) Terapeutisk anvendelige peptider og peptidfragmenter
TR199900666T2 (xx) �nsan paratormonu ile ilgili peptidlere kar�� antikor.
DE69837283D1 (de) Verwendung von einem phospatidylserine/polypeptide konjugat um autoimmunität hervorzurufen in der behandlung von krebs
PL338001A1 (en) Integrin-bonding peptides and their application
ATE68960T1 (de) Shampoo-praeparate.
EP0739350A4 (de) Fas-antigenbindender ligand
MX9703889A (es) Peptido rantes y fragmentos y composiciones que lo contienen, para el tratamiento de la inflamacion.
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
TW272197B (de)
ATE344052T1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
EP1447414A3 (de) Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität
ES2006730A6 (es) Un metodo de preparar un peptido o polipeptido sintetico que presenta la antigenicidad de la totalidad o una parte de un antigeno de p. falciparum
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
MY102593A (en) Antigents of plasmodium falciparum
DE60233654D1 (de) Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung
ES2005753A6 (es) Procedimiento para la preparacion de polipeptidos inmunologicamente activos utiles para la obtencion de vacunas antimalaria y para la deteccion de enfermedades paludicas.
TR199802168T2 (xx) IL-16 Aktivitesine sahip işlenmiş polipeptidler, bunları üretmeye mahsus yöntemler ve bunların kullanımı.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee